Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-007052
Filing Date
2026-02-17
Accepted
2026-02-17 14:54:17
Documents
72
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 2152523
2 EX-31.1 ex31-1.htm EX-31.1 30762
3 EX-32.1 ex32-1.htm EX-32.1 13589
  Complete submission text file 0001493152-26-007052.txt   10910667

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20251231.xsd EX-101.SCH 62904
5 XBRL CALCULATION FILE ppcb-20251231_cal.xml EX-101.CAL 73782
6 XBRL DEFINITION FILE ppcb-20251231_def.xml EX-101.DEF 368373
7 XBRL LABEL FILE ppcb-20251231_lab.xml EX-101.LAB 547605
8 XBRL PRESENTATION FILE ppcb-20251231_pre.xml EX-101.PRE 468411
74 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1687450
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-42806 | Film No.: 26639964
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)